A Study on the Optimal Dose of Aspirin Therapy in Kawasaki Disease: Clinical Evaluation and Arachidonic acid Metabolism

Teiji Akagi, Hirohisa Kato, Osamu Inoue, Noboru Sato

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aspirin is the basic treatment for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high-dose (lOOmg/kg/day, n = 30) versus low-dose (30 mg/kg/day, n = 30) aspirin. Duration of fever, trasaminase, plasma thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4, 7 and 14. In the high-dose group, duration of fever was significantly shorter than that of low-dose group (3.2±1.8 versus 5.4±4.3 days, p<0.05), however, serum glutamic pyruvic transaminase levels were elevated (157.4 ± 187.7 versus 48.0± 58.21. U./liter, p<0.005). No differences in the incidence of coronary artery lesions were observed (5 of 30 versus 7 of 30). Plasma TxB2 production was completely blocked in both groups, plasma 6-keto-PGF1α levels in the high-dose group on day 14 was lower than that in the low-dose group (39 α26 versus 160 α207 pg/ml, p<0.05). This latter observation suggest that high-dose therapy may be disadvantageous as anti-thrombotic treatment, and supports the notion that low dose therapy is safe in the acute stage of Kawasaki disease.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalThe Kurume Medical Journal
Volume37
Issue number3
DOIs
Publication statusPublished - Jan 1 1990
Externally publishedYes

Keywords

  • Kawasaki disease
  • aspirin
  • coronary thrombosis
  • platelet
  • prostacyclin
  • thromboxane

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A Study on the Optimal Dose of Aspirin Therapy in Kawasaki Disease: Clinical Evaluation and Arachidonic acid Metabolism'. Together they form a unique fingerprint.

  • Cite this